Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

- PMLiVE

Sanofi and Regeneron share positive data for asthma drug

The trial evaluated the drug for children aged six to 11 years with moderate-to-severe asthma

The Sofa Sessions – Fourth Page

Page & Page Health

- PMLiVE

Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials

The AI-based Lung8 imaging software picked up differences in response between patients who had an experimental drug compared with those who took a placebo

- PMLiVE

Novavax’s COVID-19 vaccine candidate receives CHMP recommendation for use as a booster

The protein-based vaccine induced a ‘robust antibody response’ when used as a heterologous third booster dose, data from a UK-sponsored trial showed

- PMLiVE

New independent survey shows strong Medscape Professional Network usage among UK doctors

The latest results of the GP and Hospital Doctor Media Surveys reveal that the Medscape Professional Network* (MPN) is amongst the leading destinations for doctors in the UK. Of those surveyed,...

Medscape Education

- PMLiVE

Medscape Oncology: at the core of cancer education #ESMO22

Medscape Education Global to Deliver Educational Opportunities at European Society for Medical Oncology (ESMO) 2022

Medscape Education

- PMLiVE

Pfizer/BioNTech BA.1 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Novo Nordisk to acquire Forma Therapeutics in deal worth $1.1bn

The acquisition will focus on expanding the company’s blood disorders portfolio

- PMLiVE

Moderna’s Omicron BA.1 targeting bivalent booster recommended by CHMP for use in EU

Results from a phase 2/3 trial demonstrated mRNA-1273.214 had superior neutralising antibody response against Omicron compared to the currently authorised booster

- PMLiVE

Alzheimer’s Research UK calls for urgent action to prioritise investment in last-stage dementia research

The number of participants recruited to late-stage dementia drug trials by the NIHR Clinical Research Network in England last year was around 100 times fewer than for cancer

Syapse and Genesis Research logos

Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators

Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.

Genesis Research Group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links